Earnings quality appears increasingly strained, with cumulative 10-quarter operating cash flow of roughly $87.4B trailing net income of $111.1B by about $23.7B (0.79x OCF/NI), 2027Q1 operating cash flow turning negative at -$927M, and free cash flow margin swinging from 12.6% in 2025Q4 to 2.7% in 2027Q2 amid $21.9B of 2027 working capital consumption.
Dr. Reddy's Laboratories Limited (RDY) cash flow statement — 26-year operating, investing & financing cash flows
| Metric | TTM | Mar'26 | Mar'25 | Mar'24 | Mar'23 | Mar'22 | Mar'21 | Mar'20 | Mar'19 | Mar'18 | Mar'17 | Mar'16 | Mar'15 | Mar'14 | Mar'13 | Mar'12 | Mar'11 | Mar'10 | Mar'09 | Mar'08 | Mar'07 | Mar'06 | Mar'05 | Mar'04 | Mar'03 | Mar'02 | Mar'01 |
|---|
| Cash from Operations | 30.11B | 56.65B | 46.43B | 45.43B | 58.88B | 28.11B | 35.7B | 29.84B | 28.7B | 18.03B | 21.51B | 41.25B | 25.03B | 19.46B | 13.32B | 16.15B | 8.01B | 13.23B | 4.5B | 6.12B | 11.83B | 1.65B | 2.29B | 4.01B | 4.35B | 4.65B | 614.87M |
| Operating CF Margin % | - | 16.03% | 14.26% | 16.27% | 23.94% | 13.11% | 1397% | 17.09% | 18.66% | 12.69% | 15.28% | 26.66% | 16.89% | 14.73% | 11.45% | 16.69% | 10.72% | 18.82% | 6.49% | 12.24% | 18.13% | 6.77% | 11.77% | 19.92% | 24.17% | 27.99% | 5.62% |
| Operating CF Growth % | -141.25% | 22.01% | 2.19% | -22.83% | 109.46% | -21.27% | 19.64% | 3.96% | 59.21% | -16.19% | -47.84% | 64.77% | 28.62% | 46.15% | -17.54% | 101.65% | -39.45% | 193.58% | -26.42% | -48.26% | 618.25% | -28.11% | -42.82% | -7.95% | -6.32% | 655.88% | - |
| Net Income | 28.03B | 45.09B | 57.24B | 55.68B | 45.07B | 23.57B | 17.24B | 19.5B | 18.8B | 9.81B | 12.04B | 20.01B | 22.18B | 21.51B | 16.78B | 14.26B | 11.04B | 1.07B | -5.17B | 4.68B | 9.35B | 1.63B | 211.27M | 2.48B | 3.52B | 4.92B | 739.28M |
| Depreciation & Amortization | 21.51B | 21.68B | 17.06B | 14.84B | 12.64B | 11.82B | 12.8B | 12.47B | 12.19B | 11.71B | 11.28B | 10.25B | 8.1B | 7.11B | 5.55B | 5.21B | 4.15B | 4.16B | 3.81B | 6.2B | 3.02B | 1.57B | 1.31B | 1.13B | 1.01B | 945.26M | 892.6M |
| Stock-Based Compensation | 117M | 0 | 424M | 407M | 397M | 592M | 584M | 521M | 389M | 454M | 398M | 471M | 498M | 436M | 390M | 326M | 265M | 226M | 131M | 257.79M | 175.38M | 162.25M | 144M | 147.73B | 0 | 0 | 0 |
| Deferred Taxes | 4.71B | 0 | 19.54B | 16.19B | 15.3B | 8.73B | 9.18B | -1.47B | 3.65B | 4.54B | 2.61B | 7.13B | 5.98B | 5.09B | 4.9B | 4.2B | 1.4B | 985M | 1.17B | -2.35B | -1.11B | -55.3M | -95.59M | -135.14M | 568.72K | -268.29M | 19.46M |
| Other Non-Cash Items | -1.66B | 2.12B | -17.85B | -21.5B | -6.67B | -2.69B | 6.63B | 6.35B | -547M | 488M | 535M | 3.57B | 3.31B | -4.3B | -1.15B | 1.1B | -2.11B | 8.33B | 12.82B | 592.61M | 3.46B | 214.37M | 609.41M | -147.37B | 494.31M | 352.83M | -46.56K |
| Working Capital Changes | -22.28B | -12.24B | -29.99B | -20.18B | -7.86B | -13.91B | -10.72B | -7.54B | -5.77B | -8.96B | -5.35B | -188M | -15.04B | -10.39B | -13.15B | -8.96B | -6.74B | -1.55B | -8.27B | -3.26B | -3.06B | -1.88B | 113.23M | 168.46M | -677.77M | -1.3B | -1.29B |
| Change in Receivables | 1.39B | -7.07B | -10.28B | -8.05B | -5.75B | -17.01B | 2.08B | -12.45B | 1.8B | -2.1B | 3.04B | 833M | -10.9B | 118M | 2M | 3M | -4.58B | 900M | -7.35B | 226.93M | 151.62M | 33.63M | 79.44M | 19.87B | 93.88B | 0 | 0 |
| Change in Inventory | -10.49B | -9.05B | -12.75B | -18.45B | -2.65B | -5.33B | -12.4B | -1.49B | -8.5B | -3.23B | -6.33B | -2.52B | -5.45B | -3.97B | -3.87B | -4.35B | -3.62B | -1.59B | -1.94B | -3.91B | -997.71M | -1.86B | -514.19M | -335.84M | -439.57M | -364.67M | -298.96M |
| Change in Payables | -7.14B | 2.94B | 0 | 0 | 0 | 17.01B | 0 | 0 | -1.8B | 0 | 0 | 0 | 0 | 0 | -4.5B | -5.97B | 1.15B | 0 | 0 | 1.08B | 889.68M | 1.51B | -763.52M | 690.18B | 584.96B | 0 | 0 |
| Cash from Investing | -31.03B | -70.53B | -58.08B | -40.28B | -41.37B | -26.39B | -22.66B | -4.92B | -7.73B | -14.88B | -18.47B | -20.42B | -22.9B | -16.62B | -13.94B | -18.66B | -8.66B | -7B | -3.47B | -9.6B | 593.86M | -34.61B | 632.88M | -6.52B | -1.95B | -1.53B | -686.95M |
| Capital Expenditures | -25.73B | -40.43B | -27.5B | -16.4B | -11.32B | -19.05B | -9.74B | -4.85B | -7.49B | -11.04B | -40.98B | -14.88B | -15.33B | -10.63B | -7.34B | -8.59B | -11.61B | -4.28B | -4.76B | -6.77B | -4.75B | -1.92B | -1.75B | -2.42B | -1.51B | -1.09B | -487.2M |
| CapEx % of Revenue | 7.77% | 11.44% | 8.45% | 5.88% | 4.61% | 8.89% | 381.15% | 2.78% | 4.87% | 7.78% | 29.11% | 9.61% | 10.34% | 8.04% | 6.31% | 8.87% | 15.54% | 6.09% | 6.86% | 13.54% | 7.28% | 7.89% | 8.98% | 12.03% | 8.39% | 6.56% | 4.46% |
| Acquisitions | -2.74B | -2.99B | -53.41B | -12M | 0 | -326M | -15.51B | 0 | 536M | 1.75B | -103M | -7.94B | -276M | 546M | -1.75B | 1.73B | -1.17B | -93M | -3.17B | 55.04M | 84.24M | -27.34B | -535.68M | -9.46M | -346.68M | 49.26M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 4.64B | 1.47B | -2.28B | -8.16B | -6.68B | 4.19B | -1.51B | 137M | 1.51B | -1.2B | 672M | 1.37B | 989M | 551M | 1.17B | -1.23B | 475M | 387M | 456M | 496.68M | 5.42B | -5.56B | 64.72M | -6.16M | -97.16M | -404.48M | 75.43M |
| Cash from Financing | 3.08B | 13.4B | 18.91B | -3.76B | -26.86B | -2.42B | -298M | -25.16B | -21.33B | -4.44B | -3.69B | -17B | -4.12B | -217M | -1.79B | 3.73B | -377M | -5.31B | -2.53B | -6.83B | 1.76B | 27.28B | 1.93B | -376.92M | -152.56M | 1.42B | -87.35M |
| Debt Issued (Net) | 12.6B | 21.31B | 23.2B | 4.35B | -20.4B | 2.73B | 6.09B | -19.16B | -15.18B | 882M | -5.22B | -11.98B | -3.72B | 3.96B | 2.29B | 7.05B | 8.68B | -3.56B | -1.79B | -7.14B | -7.78B | 27.99B | 2.36B | 166.33M | 38.15M | -3.8B | 46.65M |
| Equity Issued (Net) | 426.48M | 417.73M | -1.2B | 805M | 368M | 334M | -924M | -470M | -535M | 1M | -15.69B | 1M | 0 | 2M | 1M | 6M | 29M | 17M | 5M | 15M | 10.05B | 73.83M | 0 | -110.76M | 0 | 5.78B | 0 |
| Dividends Paid | -6.64B | -7.01B | -6.66B | -6.65B | -4.98B | -4.15B | -4.15B | -3.92B | -4B | -3.99B | -3.39B | -4.11B | -3.07B | -2.98B | -2.71B | -2.22B | -3.06B | -1.23B | -738M | -737.28M | -438.54M | -437.48M | -431.62M | -432.54M | -190.76M | -561.04M | -134M |
| Share Repurchases | 0 | 0 | -1.39B | 0 | 0 | 0 | -1.19B | -474M | -535M | 0 | -15.69B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -116.23M | 0 | 0 | 0 |
| Other Financing | -3.31B | -1.33B | 3.57B | -2.27B | -1.85B | -1.34B | -1.32B | -1.61B | -1.61B | -1.33B | 20.61B | -1.61B | 3.19B | -1.19B | -1.37B | -1.11B | -6.02B | -529M | 0 | 287K | -79.23M | -341.1M | 0 | 43.38K | -152.87B | -48.73K | 0 |
| Net Change in Cash | 2.29B | -875.84M | 7.49B | 1.33B | -9.07B | 32M | 12.86B | -266M | -314M | -1.24B | -1.14B | -473M | -3.06B | 3.4B | -2.33B | 1.72B | -885M | 1.17B | -1.61B | -10.58B | 14.3B | -5.59B | 4.91B | -2.9B | 2.16B | 4.63B | -78.27M |
| Free Cash Flow | 12.01B | 32.1B | 12.03B | 18B | 40.01B | 9.06B | 23.14B | 23.73B | 21.21B | 6.99B | -19.47B | 26.37B | 9.71B | 8.84B | 5.98B | 7.57B | -3.6B | 8.94B | -256M | -646.96M | 7.08B | -272.35M | 542.45M | 1.59B | 2.84B | 3.56B | 127.67M |
| FCF Margin % | 3.63% | 9.08% | 3.7% | 6.45% | 16.27% | 4.23% | 905.51% | 13.59% | 13.79% | 4.92% | -13.83% | 17.05% | 6.55% | 6.69% | 5.14% | 7.82% | -4.82% | 12.73% | -0.37% | -1.29% | 10.86% | -1.12% | 2.79% | 7.89% | 15.78% | 21.43% | 1.17% |
| FCF Growth % | -34.96% | 166.85% | -33.16% | -55.02% | 341.65% | -60.85% | -2.46% | 11.85% | 203.65% | 135.88% | -173.83% | 171.71% | 9.85% | 47.73% | -20.94% | 310.31% | -140.22% | 3593.36% | 60.43% | -109.13% | 2701.43% | -150.21% | -65.82% | -44.17% | -20.11% | 2687.35% | - |
| FCF per Share | 14.42 | 38.53 | 14.42 | 21.59 | 48.09 | 10.89 | 27.83 | 28.57 | 25.53 | 8.41 | -23.32 | 30.83 | 11.36 | 10.35 | 7.02 | 8.89 | -4.23 | 10.54 | -0.30 | -0.77 | 8.90 | -0.36 | 0.71 | 2.07 | 3.72 | 4.67 | 0.20 |
| FCF Conversion (FCF/Net Income) | 0.43x | 1.26x | 0.82x | 0.82x | 1.31x | 1.19x | 153.75x | 1.53x | 1.53x | 1.84x | 1.79x | 2.06x | 1.13x | 0.90x | 0.79x | 1.13x | 0.73x | 12.38x | -0.87x | 1.31x | 1.27x | 1.01x | 10.85x | 1.62x | 1.24x | 0.95x | 0.83x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying RDY stock.
Dr. Reddy's Laboratories Limited (RDY) generated $56.65B in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.
Dr. Reddy's Laboratories Limited (RDY) generated $32.10B in free cash flow in 2026. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Dr. Reddy's Laboratories Limited (RDY) spent $40.43B on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2026, Dr. Reddy's Laboratories Limited (RDY) returned $7.01B to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Working capital drain undermining cash conversion
Earnings-Cash Gap Widens Sharply
Dr. Reddy's operating cash flow collapsed to negative $927M in 2027Q1 against $4.5B in net income, producing an OCF/NI ratio of -0.21, while cumulative 10-quarter OCF of approximately $87.4B trails cumulative net income of $111.1B by roughly $24B, suggesting structurally accrual-heavy earnings.
The sequential deterioration from an OCF/NI ratio of 6.91 in 2026Q4 to -0.21 in 2027Q1 and then 0.51 in 2027Q2 represents a fundamental breakdown in cash conversion that cannot be explained by seasonality alone. The 2026Q4 spike to 6.91 coincided with a $7.8B working capital release and a $15.4B OCF on only $2.2B of net income, indicating that the reported figure was driven by balance sheet unwinding rather than operating performance. The cumulative gap of approximately 21% between net income and operating cash flow over the 10-quarter window suggests that reported earnings may be persistently overstated relative to realized cash collections, a pattern consistent with aggressive revenue recognition on chargebacks and shelf-stock provisions as flagged in the prior income statement analysis.
FCF Volatility Signals Erosion
Free cash flow has swung from $10.8B in 2025Q4 to negative $4.6B in 2027Q1, with the most recent quarter recovering to only $2.3B at a 2.7% FCF margin, well below the 12.6% margin recorded in 2025Q4, reflecting both working capital consumption and elevated capital expenditure.
The FCF trajectory shows a clear pattern of diminishing quality — the $10.8B FCF in 2025Q4 was inflated by a $584M working capital release and modest capex, while the $10.7B in 2026Q4 similarly benefited from a $7.8B working capital release. Excluding these releases, underlying FCF generation appears materially weaker. The 2027Q1 negative FCF of -$4.6B, driven by a -$12.0B working capital swing combined with $3.4B of capex on only $4.5B of net income, represents a severe cash stress event. While 2027Q2 shows nominal recovery at $2.3B FCF, the 2.7% margin remains depressed relative to the 6-7% range seen in mid-2026, suggesting the trajectory is deteriorating rather than stabilizing.
Working Capital Swings Destabilize Liquidity
Dr. Reddy's working capital consumed $21.9B across 2027Q1 and 2027Q2 combined, reversing a $7.8B release in 2026Q4, with cumulative working capital changes over 10 quarters swinging between -$13.1B and +$7.8B, reflecting severe operational unpredictability in inventory and receivables management.
The magnitude of these working capital swings is extraordinary relative to the company's net income base and suggests that the underlying business is experiencing significant volatility in either collection cycles, inventory positioning, or provisioning dynamics — or some combination thereof. The -$13.1B drain in 2025Q1 followed by -$7.8B in 2025Q2 and then positive $584M in 2025Q4 indicates a business where working capital needs are not predictable on a quarter-to-quarter basis, making cash flow forecasting inherently unreliable. The recent back-to-back drains of -$12.0B and -$9.9B in 2027 align with the revenue contraction noted in the prior income statement analysis, which could suggest receivables buildup from slower-paying US wholesaler channels or inventory accumulation tied to declining sell-through — both warrant further investigation into the company's disclosure of provisions for sales returns and shelf-stock adjustments.
Cumulative Earnings Overstate Cash Reality
Over the 10-quarter period, Dr. Reddy's cumulative net income of approximately $111.1B exceeded cumulative operating cash flow of $87.4B by roughly $23.7B, yielding a cumulative OCF/NI ratio of approximately 0.79 and indicating that the quality of reported earnings has been persistently substandard.
A cumulative OCF/NI ratio below 1.0 across a full cycle is a classic indicator of accrual-based earnings inflation, where revenue is recognized before cash is collected or expenses are deferred. The gap is particularly acute when the $51.8B acquisition in 2025Q2 is excluded from the analysis, as that transaction would have reduced OCF through any associated working capital adjustments. The divergence suggests that the prior income statement analysis finding of gross margin compression to 52.77% may actually understate the economic deterioration, because the cash conversion gap implies that even the compressed reported margins are not fully translating into realized cash. Investors should monitor whether this gap narrows in subsequent quarters; persistent divergence at this magnitude would raise questions about the durability of the reported earnings base.
SBC Inconsistency and D&A-Capex Mismatch Obscure True Economics
Stock-based compensation was reported as $0 in 2027Q2 and 2026Q4 despite $97M to $113M in adjacent quarters, while quarterly depreciation and amortization of $3.8-5.7B consistently exceeds maintenance capex, suggesting the cash flow statement may not fully reflect the economic cost of asset consumption or equity compensation.
The erratic SBC reporting — oscillating between $0 and $113M across quarters — complicates any attempt to construct a clean adjusted cash flow picture, as zero SBC in quarters with $9-15B of net income is difficult to reconcile with a pharmaceutical company's typical equity compensation structure. More significantly, D&A has grown from $3.8B to $5.7B quarterly while capex has been volatile in the $3.4-11.3B range; in quarters where capex falls below D&A (such as 2027Q1 at $3.4B capex vs. $5.4B D&A), the company may be underinvesting in productive capacity relative to asset consumption, which would further erode the quality of future earnings. The $647.8M positive acquisition cash flow in 2027Q2 (indicating asset disposals) alongside a $3.2B acquisition outflow in 2026Q4 suggests portfolio reshuffling that could be generating non-recurring cash inflows masking operational weakness.